<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">101610773</journal-id>
<journal-id journal-id-type="pubmed-jr-id">41531</journal-id>
<journal-id journal-id-type="nlm-ta">Curr Psychopharmacol</journal-id>
<journal-id journal-id-type="iso-abbrev">Curr Psychopharmacol</journal-id>
<journal-title-group>
<journal-title>Current psychopharmacology</journal-title>
</journal-title-group>
<issn pub-type="ppub">2211-5560</issn>
<issn pub-type="epub">2211-5579</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">32432025</article-id>
<article-id pub-id-type="pmc">7236426</article-id>
<article-id pub-id-type="manuscript">VAPA1587040</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>In Search of Reward Deficiency Syndrome (RDS)-free Controls: The “Holy Grail” in Genetic Addiction Risk Testing</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Blum</surname>
<given-names>Kenneth</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="aff" rid="A4">4</xref>
<xref ref-type="aff" rid="A5">5</xref>
<xref ref-type="aff" rid="A6">6</xref>
<xref ref-type="aff" rid="A7">7</xref>
<xref ref-type="aff" rid="A8">8</xref>
<xref ref-type="aff" rid="A9">9</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Baron</surname>
<given-names>David</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lott</surname>
<given-names>Lisa</given-names>
</name>
<xref ref-type="aff" rid="A7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ponce</surname>
<given-names>Jessica V.</given-names>
</name>
<xref ref-type="aff" rid="A7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Siwicki</surname>
<given-names>David</given-names>
</name>
<xref ref-type="aff" rid="A7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Boyett</surname>
<given-names>Brent</given-names>
</name>
<xref ref-type="aff" rid="A8">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Steinberg</surname>
<given-names>Bruce</given-names>
</name>
<xref ref-type="aff" rid="A10">10</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Modestino</surname>
<given-names>Edward J.</given-names>
</name>
<xref ref-type="aff" rid="A10">10</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fried</surname>
<given-names>Lyle</given-names>
</name>
<xref ref-type="aff" rid="A11">11</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hauser</surname>
<given-names>Mary</given-names>
</name>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Simpatico</surname>
<given-names>Thomas</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Downs</surname>
<given-names>Bill W.</given-names>
</name>
<xref ref-type="aff" rid="A9">9</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>McLaughlin</surname>
<given-names>Thomas</given-names>
</name>
<xref ref-type="aff" rid="A12">12</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hajela</surname>
<given-names>Raju</given-names>
</name>
<xref ref-type="aff" rid="A13">13</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Badgaiyan</surname>
<given-names>Rajendra D.</given-names>
</name>
<xref ref-type="aff" rid="A14">14</xref>
<xref ref-type="aff" rid="A15">15</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Graduate School of Biomedical Science, Western University Health Sciences, Pomona, CA, USA;</aff>
<aff id="A2"><label>2</label>Eotvos Loránd University, Institute of Psychology, Budapest, Hungary;</aff>
<aff id="A3"><label>3</label>Department of Psychiatry, Wright State University Boonshoft School of Medicine and Dayton VA Medical Center, Dayton, OH, USA;</aff>
<aff id="A4"><label>4</label>Department of Psychiatry, University of Vermont, Burlington, VT, USA;</aff>
<aff id="A5"><label>5</label>Division of Clinical Neurology, PATH Foundation, New York, NY, USA;</aff>
<aff id="A6"><label>6</label>Dominion Diagnostics, North Kingston, RI, USA;</aff>
<aff id="A7"><label>7</label>Division of Precision Addiction Management, Geneus Health, San Antonio, TX, USA;</aff>
<aff id="A8"><label>8</label>Division of Neuroscience &amp; Addiction Therapy Research, Pathway HealthCare, Birmingham, AL, USA;</aff>
<aff id="A9"><label>9</label>Victory Nutrition International, Inc., Lederach, PA, USA;</aff>
<aff id="A10"><label>10</label>Department of Psychology, Curry College, Milton, MA, USA;</aff>
<aff id="A11"><label>11</label>Transformations Treatment Center, Delray Beach, FL, USA;</aff>
<aff id="A12"><label>12</label>Center for Psychiatric Medicine, Lawrence, MA, USA;</aff>
<aff id="A13"><label>13</label>Department of Family Medicine, Cummings School of Medicine, University of Calgary, Calgary, CN, Canada;</aff>
<aff id="A14"><label>14</label>Department of Psychiatry, South Texas Veteran Health Care System, Audie L. Murphy Memorial VA Hospital, and Long School of Medicine, University of Texas Medical Center, San Antonio, TX, USA;</aff>
<aff id="A15"><label>15</label>Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA</aff>
<author-notes>
<corresp id="CR1"><label>*</label>Address correspondence to this author at the Graduate School of Biomedical Science, Western University Health Sciences, Pomona, CA, USA; Tel: 6198902167; Fax: 5122360873; <email>drd2gene@gmail.com</email></corresp>
<fn fn-type="COI-statement" id="FN4">
<p id="P46">CONFLICT OF INTEREST</p>
<p id="P47">Dr. Blum is the inventor of GARS and along with Dr. Siwicki own Geneus Health. Lisa Lott and Jessica Ponce are paid by Geneus Health.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>24</day>
<month>4</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="ppub">
<year>2020</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>19</day>
<month>5</month>
<year>2020</year>
</pub-date>
<volume>9</volume>
<issue>1</issue>
<fpage>7</fpage>
<lpage>21</lpage>
<abstract id="ABS1">
<sec id="S1">
<title>Background:</title>
<p id="P1">The search for an accurate, gene-based test to identify heritable risk factors for Reward Deficiency Syndrome (RDS) was conducted based on hundreds of published studies about the role of dopamine in addictive behaviors, including risk for drug dependence and compulsive/impulsive behavior disorders. The term RDS was first coined by Blum’s group in 1995 to identify a group of behaviors with a common neurobiological mechanism associated with a polymorphic allelic propensity for hypodopaminergia.</p>
</sec>
<sec id="S2">
<title>Objectives:</title>
<p id="P2">To outline the process used to select risk alleles of reward genes for the Genetic Addiction Risk Score (GARS) test. Consequently, to address the limitations caused by inconsistent results that occur in many case-control behavioral association studies. These limitations are perhaps due to the failure of investigators to adequately screen controls for drug and alcohol use disorder, and any of the many RDS behaviors, including nicotine dependence, obesity, pathological gambling, and internet gaming addiction.</p>
</sec>
<sec id="S3">
<title>Methods:</title>
<p id="P3">Review of the literature related to the function of risk alleles of reward genes associated with hypodopaminergia relevant case-control association studies for the selection of alleles to be measured by the Genetic Addiction Risk Score (GARS) test.</p>
</sec>
<sec id="S4">
<title>Results:</title>
<p id="P4">The prevalence of the DRD2 A1 allele in unscreened controls (33.3%), compared to “Super-Controls” [highly screened RDS controls (3.3%) in proband and family] is used to exemplify a possible solution.</p>
</sec>
<sec id="S5">
<title>Conclusion:</title>
<p id="P5">Unlike one gene-one disease (OGOD), RDS is polygenetic, and very complex. In addition, any RDS-related behaviors must be eliminated from the control group in order to obtain the best possible statistical analysis instead of comparing the phenotype with disease-ridden controls.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Behavioral genetic research</kwd>
<kwd>case controlled studies</kwd>
<kwd>genetic addiction association studies</kwd>
<kwd>genetic prevalence</kwd>
<kwd>hypodopaminergia</kwd>
<kwd>Reward Deficiency Syndrome (RDS)</kwd>
<kwd>Single Nucleotide Polymorphisms (SNPs)</kwd>
<kwd>study controls</kwd>
<kwd>super controls</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>